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Abstract 
Background: The SUSPPUP ratio ([serum sodium/urinary sodium]/[serum 
potassium²/urinary potassium]) has been proposed as a marker to screen for primary 
aldosteronism (PA). The original study found an area under the receiver operating 
characteristic (ROC) curve of 0.90 to detect PA; the sensitivity was 89% and specificity 86% 
for a ratio over 5.3 l/mmol.  
Materials and methods: Patients attending a hypertension unit between 2001 and 2006 and 
for who renin and aldosterone measurements and concomitant serum and urinary 
biochemistry data were available were included if diagnosed with PA (n=449) or essential 
hypertension (n=2209). We compared the diagnostic value of the SUSPPUP ratio and of 
serum potassium in the whole population, in patients without interfering drugs and in patients 
with lateralized PA.  
Results: The area under the ROC curve was significantly worse for the SUSPPUP ratio than 
for serum potassium in all groups: 0.72 vs. 0.76 in the whole population; 0.73 vs. 0.78 without 
interfering drugs; 0.76 vs. 0.82 for patients with lateralized PA.  
In the whole population, sensitivity was 71% for a SUPPUP ratio ≥ 5.3 l/mmol and serum 
potassium < 3.7 mmol/l, but specificity of the SUSPPUP ratio was significantly worse (61% 
vs. 69%). Using low serum potassium and/or high SUSPPUP ratio increased the sensitivity to 
87% but decreased the specificity to 47%. 
Conclusions: The SUSPPUP ratio was outperformed by serum potassium as a screening tool 
for PA in this large validation sample. Its value as an adjunct to serum potassium is 
questionable because of the low specificity of their combination. 
Keywords 
Hypertension; primary aldosteronism; potassium, blood; potassium, urine; diagnosis; 
sensitivity and specificity  
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Introduction 
The frequency of primary aldosteronism (PA) is at most 10% among unselected hypertensive 
patients, and probably less [1]. The plasma aldosterone to renin ratio (ARR) is the 
recommended screening test for PA [2]. However, widespread hormonal screening would 
result in many false positives and subsequent unnecessary expensive or even harmful 
diagnostic procedures [3, 4]. Guidelines therefore still advocate screening for PA only in 
cases of low serum potassium, resistant hypertension or adrenal mass [2, 5-7]. Low serum 
potassium has for a long time been considered to be a good indicator of PA, but is currently 
reported in as few as 10 to 40% of patients [8]. PA with normal serum potassium is most 
likely to be due to bilateral adrenal hyperplasia [3, 9] but lateralized PA can also present with 
normal serum potassium in a significant proportion of cases [10]. 
 
The SUSPPUP ratio ([serum sodium/urinary sodium]/[serum potassium²/urinary potassium]) 
has been proposed as a cheap tool to detect additional patients who would qualify for 
hormonal screening. The basis for this suggestion was a pathophysiological rationale: excess 
secretion of aldosterone promotes potassium secretion, and sodium and water retention. The 
SUSPPUP ratio was designed to detect relative high serum and low urinary sodium 
concentrations, along with relatively low serum and high urinary potassium concentrations. 
The original study found an area under the receiving operator characteristic (ROC) curve of 
0.90 to detect PA; the sensitivity was 89% and specificity 86% for a SUSPPUP ratio over 5.3 
l/mmol [11]. These results were supported by a second small study, where the area under the 
ROC curve was 0.87, the sensitivity was 85% and the specificity 82% for a SUSPPUP ratio 
over 5.95 l/mmol [12]. We undertook a retrospective study to validate this ratio in a large 
sample of patients with PA or essential hypertension (EH). 
 
Patients and methods 
Patients and data 
Consecutive patients who underwent renin and aldosterone measurements in our hypertension 
unit between January 1, 2001, and December 31, 2006 were retrospectively identified and 
included if finally diagnosed with PA or EH [13]. Patients for who urine biochemistry data 
were unavailable and PA patients with severely impaired renal function (estimated glomerular 
filtration rate < 30 ml/min/1.73m²) were excluded.  
 
As a general rule, renin and aldosterone measurements were performed in patients fulfilling at 
least one of the following criteria: hypertension onset at an age below 40 years old; resistant 
(BP > 140/90 mmHg on three or more antihypertensive drugs including a diuretic) or severe 
(BP > 180/110 mmHg) hypertension; or hypertension associated with serum potassium < 3.9 
mmol/l (or < 3.6 mmol/l if on thiazide or loop diuretic) [5]. 
 
Clinical data (age, sex, blood pressure, prescribed drug classes) and biological data (serum 
and urinary sodium and potassium, serum creatinine, plasma renin, plasma and urinary 
aldosterone) were collected from the first in-patient visit for a diagnostic workup for all 
patients, irrespective of their final diagnosis. Clinical data from all patients were extracted 
from the electronic health record database, where they had been entered prospectively as part 
of routine care [14]. Laboratory results were extracted from the database of the biochemistry 
department.  
 
Test methods and diagnostic criteria 
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Blood samples were drawn after washout of interfering drugs whenever possible (for at least 
two weeks for diuretics, beta-blockers, ACE inhibitors and angiotensin antagonists and at 
least six weeks for spironolactone and aliskiren). Potassium supplements were prescribed if 
required to avoid severe hypokalemia that could affect hormonal measurements. A venous 
catheter was inserted on patients’ admission and free-flowing blood was drawn after 1 hour of 
lying or seating rest. In patients with PA or EH for whom aldosterone measurements in the 
lying and sitting positions were available, we observed that both values were similar. 
Therefore, we used aldosterone and renin levels in the lying position when available and in 
the sitting position otherwise. Urinary sodium and potassium were determined from a 24-hour 
urine collection. 
 
Plasma and urinary aldosterone concentrations were determined by radioimmunoassay (Coat-
A-Count®, Siemens Medical Solutions Diagnostics); 24-hour urinary excretion of aldosterone 
was measured as the sum of free aldosterone and aldosterone from the hydrolysis of 
aldosterone 18-glucuronide at pH 1.0. Plasma active renin was determined by 
chemiluminescent immunoassay (LIAISON®, Diasorin). Serum and urinary potassium 
concentrations were determined by indirect potentiometry (Unicel DxC 800® system, 
Beckmann Coulter). All of the other biochemical variables were assayed in plasma or serum 
by standard methods.  
 
PA was diagnosed if the ARR obtained in standardized conditions was > 64 pmol/mIU (107 
pmol/ng) on two occasions, and if the plasma aldosterone concentration was > 550 pmol/l (20 
ng/dl) in the standing or sitting position, or > 500 pmol/l (18 ng/dl) in the supine position, or 
urinary aldosterone excretion was > 63 nmol/d (23 µg/d). To calculate the ARR, active renin 
concentrations < 5 mIU/l (3 ng/l) were set at 5 mIU/l to avoid ARR overestimation when 
active renin concentrations were undetectable or very low.  
 
Patients with PA were operated on the basis of a typical solitary adenoma on CT scan or of 
the results of adrenal venous sampling (AVS).  Patients were classified as having definitely 
lateralized PA (i) if the aldosterone:cortisol ratio was at least five times higher in one adrenal 
vein than the other, regardless of postoperative outcome, or (ii) if they did not undergo AVS 
but were cured by unilateral adrenalectomy (hormonal cure when postoperative values were 
available and weaning from all antihypertensive drugs with resolution of hypertension and 
hypokalemia in other cases). 
 
Secondary hypertension was ruled out by a standardised work-up to allow the diagnosis of 
EH. Renovascular hypertension was defined as renal artery stenosis exceeding a 60% 
reduction in luminal diameter (due to atherosclerosis of fibromuscular dysplasia) on contrast 
CT scan. Hypertension was considered secondary to chronic kidney disease in patients with 
pre-existing parenchymal renal disease, indicated by an estimated glomerular filtration rate < 
60 ml/min/1.73m² or proteinuria. Cushing syndrome was excluded by urinary free cortisol < 
250 nmol/d and pheochromocytoma by a urinary metanephrines:creatinine ratio < 0.354 [15]. 
 
Statistical analysis 
Our first objective was to compare the areas under the ROC curve of the SUSPPUP ratio and 
of serum potassium for the diagnosis of PA. We ascertained that our sample size was 
sufficient for statistically and clinically meaningful conclusions. Given our sample size, we 
could expect standard errors of at most 0.015 for our areas under the ROC curves. This 
allowed a power over 0.99 to show a difference of 0.1 or more between areas under the ROC 
curves of the SUSPPUP ratio and serum potassium (with an α–level at 0.05).  
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The secondary objective was to compare the diagnostic accuracy (sensitivity and specificity) 
of these tests. For these computations, the threshold was set at 5.3 l/mmol for the SUSPPUP 
ratio, as suggested by the original publication [11]. We also evaluated the SUSPPUP ratio 
with the threshold at 5.95 l/mmol, reported as optimal in another study [12], and at the 
threshold with the best Youden index (sensitivity + specificity − 1) in our population. French 
guidelines recommend looking for PA in cases with serum potassium < 3.9 mmol/l without 
thiazide or loop diuretic, or < 3.6 mmol/l under such diuretics [5]. The comparison with the 
SUSPPUP ratio required the use of a single threshold value and we chose the intermediate 
value of 3.7 mmol/l. 
 
We compared the diagnostic values of the SUSPPUP ratio and of serum potassium in the 
whole population, in patients without interfering drugs and in patients with lateralized PA. 
These two subgroups were chosen because patients were weaned from interfering drugs in the 
original study [11], and because missing patients with bilateral PA is of less importance than 
missing patients with lateralized PA, who can benefit from surgery. We also evaluated the 
added value of the SUSPPUP ratio to identify PA patients with normal serum potassium. 
 
Descriptive statistics are reported as medians (interquartile range) or numbers (percentage), as 
appropriate, and differences were evaluated by the Mann-Whitney and the Chi-square tests, 
respectively. Areas under the ROC curve for the diagnosis of PA and their 95% confidence 
intervals were computed for the SUSPPUP ratio and serum potassium, and compared as 
proposed by Hanley and McNeil [16]. The sensitivity and specificity of tests were compared 
with the McNemar Chi-square. All statistical analyses were performed with Stata 9.2 
(StataCorp, Texas). 
 
The reporting of this study complies with the STARD statement (STAndards for the 
Reporting of Diagnostic accuracy studies) [17, 18]. 
 
Results 
During the study period, 459 patients were diagnosed with PA and 2275 patients had a 
complete workup excluding secondary hypertension. Urinary biochemistry or serum sodium 
data was missing for 10 patients with PA and 87 patients with EH. Five other PA patients had 
an estimated GFR < 30 ml/min/1.73 m². We therefore included 444 patients with PA and 
2188 patients with EH in the study.  
 
Their clinical, biochemical and hormonal characteristics are given in Table 1. Patients with 
PA had significantly lower plasma potassium concentrations and higher SUSPPUP ratios than 
patients with EH, but the distributions overlapped.  
 
PA was lateralized in 115 patients; these patients differed from those for other PA patients for 
the following biochemical and hormonal variables: serum potassium (3.3 [interquartile range: 
3.0, 3.6] mmol/l in patients with lateralized PA vs. 3.4 [3.2, 3.7] mmol/l in other PA patients, 
p<0.001), SUSPPUP ratio (8.5 [5.6, 13.1] vs. 6.8 [4.9, 11.0] l/mmol, p=0.01), serum 
aldosterone (644 [441, 1050]  vs. 538 [403, 739] pmol/l, p=0.002), serum renin (2.1 [1.4, 4.4]  
vs. 3.2 [1.9, 5.2] mIU/l, p=0.005), and ARR (122 [85, 193]  vs. 95 [72, 133] pmol/mIU, 
p<0.001). 
 
The area under the ROC curve and specificity of serum potassium (threshold at 3.7 mmol/l) 
were significantly better than those of the SUSPPUP ratio (threshold at 5.3 l/mmol) in the 
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whole population and in both prespecified subgroups (Table 2). In the whole population, the 
best Youden index was found for a SUSPPUP ratio at 5.1 l/mmol, with a sensitivity of 76% 
[95% CI: 71, 79] and a specificity of 57% [55, 59]; at this threshold, the sensitivity of the 
SUSPPUP ratio was similar to that of serum potassium with a threshold at 3.7 mmol/l (p = 
0.15), but the specificity was significantly worse (p < 0.001). With a threshold at 5.95 l/mmol, 
the SUSPPUP ratio had a sensitivity of 63% [58, 68] and a specificity of 69% [67, 71] in the 
whole population; this specificity was similar to that of serum potassium with a threshold at 
3.7 mmol/l (p = 0.68), but the sensitivity was significantly worse (p = 0.001). 
 
A SUSPPUP ratio ≥ 5.3 l/mmol was observed in about half of the patients with false negative 
serum potassium results (Table 3.A). Considering that patients were screen-positive if they 
had a serum potassium < 3.7 mmol/l or a serum potassium ≥ 3.7 mmol/l but a SUSPPUP ratio 
≥ 5.3 l/mmol significantly increased the overall sensitivity to 87% [95% CI: 84, 90] but also 
significantly decreased the specificity to 47% [45, 49]. 
 
Discussion 
Main results 
The SUSPPUP ratio was less accurate than serum potassium to distinguish PA or lateralized 
PA from EH in this population, owing to a worse specificity for a similar sensitivity or a 
worse sensitivity for a similar specificity, depending on the choice of the threshold values. 
Results did not differ significantly in patients who were assessed after washout of interfering 
drugs. The distribution of serum potassium and the SUSPPUP ratio suggested there may 
potentially be value in combining these two tests. However, although using the SUSPPUP 
ratio for patients with normal serum potassium significantly increased sensitivity, it also 
decreased specificity compared to using serum potassium values alone. As a result, many 
additional patients would be investigated for PA but only a few of these would be confirmed. 
 
Comparison with previous studies 
The SUSPPUP performed worse in our population than in the original study where the area 
under the ROC curve was 0.90 [11], or than in the subsequent study where the area under the 
ROC curve was 0.87 [12]. Several differences in protocol and in population between the 
original study and ours must be outlined. 
 
We determined the SUSPPUP ratio with urinary sodium and potassium concentrations 
measured from 24-hour urine, whereas a sample of the second miction urine was used in the 
original study [11]. Although 24-hour urine collections are usually considered as the reference 
for sodium and potassium measurements, second miction samples may give slightly different 
and more useful information for the SUSPPUP ratio. However, the fact that Balas et al., who 
also used 24-h urine, found a diagnostic value close to the original study argues against this 
hypothesis [12].  
 
Our control patients with EH were selected patients referred to a hypertension unit, in whom 
hormonal screening was indicated according to guidelines. This may have decreased the 
specificity of the SUSPPUP ratio, but would then also have decreased the specificity of serum 
potassium. Moreover, our patients with PA were not selected and much more numerous than 
in the original study. We therefore consider our estimate of the sensitivity of the SUSPPUP 
ratio to be more representative and precise than that of the original study. Not all patients 
could be assessed without interfering drugs, but results were similar when only patients 
without interfering drugs were considered.  
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The diagnostic value of the SUSPPUP ratio may have been overestimated in the original 
study, because of two potential levels of overfitting. First, the best threshold observed in the 
original study may differ from the true value due to the inaccuracies of estimates in a small 
sample. Second, the original study did not only evaluate the SUSPPUP ratio, but also the 
SUSPUP ratio (where urinary potassium is not squared). When several prediction models are 
evaluated in a small data sample, there is again a risk of selecting the model that fits better 
with the sample rather than the truly best one. 
 
Study limits 
A recent guideline advocates the use of suppression tests to confirm PA in patients with a 
high ARR [2], but the evidence to support this recommendation is weak. We rather require 
the demonstration of high levels of plasma or urinary aldosterone to confirm PA [19]. 
Nonetheless, our findings hold true in the large subgroup of patients with lateralized 
aldosterone hypersecretion, in whom the diagnosis of PA can be regarded as well established. 
 
The distribution of serum potassium in PA patients varies widely among series, as illustrated 
by differing frequencies of hypokalemia. In a large study with very stringent criteria for PA 
and a very careful blood sampling procedure (no tourniquet, no fist clenching), only 30% of 
PA patients had a serum potassium ≤ 3.5 mmol/l [9]. By contrast, 69% of PA patients had a 
serum potassium ≤ 3.5 mmol/l in the original study evaluating the SUSPPUP ratio [11] and 
54% in the current series. Although the observed sensitivity of serum potassium and that of 
the SUSPPUP ratio depend on the distribution of serum potassium in the study population, 
this does not necessarily change the result of their comparison if both tests are affected 
similarly. Our results in patients with lateralized PA support this hypothesis: serum potassium 
and the SUSPPUP ratio had a higher sensitivity in this more severe subgroup than in the 
overall population, but the changes were similar for both tests and did not affect their 
comparison. 
 
Implications for clinical practice and future research 
Most of the hypertensive patients enrolled in this or in the original study were already being 
treated for hypertension. As numerous antihypertensive treatments interact with the renin – 
angiotensin – aldosterone system and influence serum potassium and sodium levels, attempts 
were made in both studies to withdraw interfering drugs before biochemical and hormonal 
investigations. Once this effort has been made, it seems sensible to determine the 
aldosterone:renin ratio regardless of any prior test like the SUSPPUP ratio.  
 
A more relevant issue is whether the SUSPPUP ratio could identify patients with newly 
diagnosed hypertension for who hormonal screening could possibly be performed beyond 
current indications (onset before 30 years old, severe hypertension from the onset, low serum 
potassium at diagnosis). Neither the first study nor ours provide a definite answer to this 
question, but the pathophysiological reasoning proposed to support the SUSPPUP ratio is 
questionable. PA is a chronic disease and patients are assessed in a steady-state. Assuming no 
gastro-intestinal loss, sodium and potassium in the urine reflect no more than sodium and 
potassium consumption. Patients with PA and patients with EH are therefore likely to have 
comparable urinary biochemistry if they eat comparable diets. By contrast, serum sodium is 
consistently higher in patients with PA than in patients with EH; consequently, it may indeed 
be useful to consider serum sodium as well as serum potassium to increase the diagnostic 
yield. However, the SUSPPUP ratio is not very sensitive to changes in serum sodium: a 
clinically significant increase from 137 to 143 mmol/l, for example, results only in a 4% 
increase of the SUSPPUP ratio. It may be more profitable to investigate diagnostic scores or 
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rules using both biochemical data and clinical characteristics to better identify patients who 
could benefit from hormonal screening for PA.  
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 1 
Table 1. Clinical and biological characteristics of patients with primary aldosteronism 
or essential hypertension, as medians [interquartile range] or numbers (percent) 
 
 Primary aldosteronism Essential hypertension p 
Age (years) 51 [44, 58] 53 [43, 61] 0.05 
Male sex 295 (66%) 1162 (53%) < 0.001 
Non-interfering treatment 321 (76%) * 1445 (66%) < 0.001 
Systolic BP (mmHg) 148 [134, 166] 148 [133, 166] 0.84 
Diastolic BP (mmHg) 88 [79, 96] 86 [78, 96] 0.32 
GFR (ml/min/1.73m²) 86 [71, 100] 86 [73, 99] 0.56 
Serum potassium (mmol/l) 3.4 [3.1, 3.7] 3.8 [3.6, 4.0] < 0.001 
Serum sodium (mmol/l) 141 [140, 143] 140 [139, 142] < 0.001 
Urinary potassium (mmol/l) 43 [32, 57] 39 [29, 54] 0.002 
Urinary sodium (mmol/l) 72 [51, 94] 83 [60, 114] < 0.001 
SUSPPUP ratio (l/mmol) 7.1 [5.1, 11.4] 4.6 [3.4, 6.5] < 0.001 
Plasma aldosterone (pmol/l) 556 [407, 779] 236 [157, 330] < 0.001 
Plasma renin (mUI/l) 3 [1.6, 4.9] 9.1 [4.3, 17.2] < 0.001 
ARR (pmol/mUI) 101 [73, 143] 23 [13, 39] < 0.001 
 
* Data on treatment was unavailable for 19 PA patients 
 
BP: Blood Pressure; GFR: Glomerular Filtration Rate; SUSPPUP ratio: (serum sodium/urinary 
sodium)/(serum potassium²/urinary potassium); ARR: Aldosterone to Renin Ratio 
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Table 2. Accuracy of the SUSPPUP ratio and of serum potassium to diagnose primary 
aldosteronism 
 
 High SUSPPUP ratio Low serum potassium p 
Whole population    
AUC [95% CI] 0.72 [0.69, 0.75] 0.76 [0.74, 0.79] 0.003 
Sensitivity [95% CI] * 71% [67, 76] 72% [67, 76] 0.87 
Specificity [95% CI] * 61% [59, 63] 69% [67, 71] <0.001 
Neutral treatment    
AUC [95% CI] 0.73 [0.70, 0.76] 0.78 [0.75, 0.81] 0.01 
Sensitivity [95% CI] * 74% [69, 79] 74% [69, 78] 0.92 
Specificity [95% CI] * 60% [57, 62] 70% [67, 72] <0.001 
Lateralized PA    
AUC [95% CI] 0.76 [0.72, 0.81] 0.82 [0.77, 0.86] 0.04 
Sensitivity [95% CI] * 79% [70, 86] 80% [72, 87] 0.72 
Specificity [95% CI] * 61% [59, 63] 69% [67, 71] <0.001 
 
*
 threshold 5.3 l/mmol for the SUSPPUP ratio and 3.7 mmol/l for serum potassium 
 
SUSPPUP ratio: (serum sodium/urinary sodium)/(serum potassium²/urinary potassium); 
AUC: area under the ROC curve; CI: confidence interval; PA: primary aldosteronism 
 
 1 
Table 3. SUSPPUP ratio and serum potassium in the overall study population 
 
A. Primary aldosteronism SUSPPUP ratio 
< 5.3 l/mmol 
SUSPPUP ratio 
≥ 5.3 l/mmol Total 
Serum potassium < 3.7 mmol/l 56 (13%) 69 (15%) 125 (28%) 
Serum potassium ≥ 3.7 mmol/l 71 (16%) 248 (56%) 319  (72%) 
Total 127 (29%) 317 (71%) 444 (100%) 
    
B. Essential hypertension SUSPPUP ratio 
< 5.3 l/mmol 
SUSPPUP ratio 
≥ 5.3 l/mmol Total 
Serum potassium < 3.7 mmol/l 1,027 (47%) 473 (22%) 1,500 (69%) 
Serum potassium ≥ 3.7 mmol/l 299 (14%) 389 (17%) 688 (31%) 
Total 1,326 (61%) 862 (39%) 2,188 (100%) 
 
